[@chen2022]
[@pickrell2015]
[@yamada2023]
[@geisler2020]
|
| Symbol | PACRG |
| Full Name | Parkin Co-regulated Protein |
| Alias | PARK2, Parkin Co-Regulated |
| Chromosome | 6q26 |
| NCBI Gene | 10652 |
| OMIM | 607571 |
| UniProt | Q9H0M0 |
| Protein Class | Regulatory protein, Mitophagy adaptor |
| Subcellular Location | Cytosol, Mitochondria |
| Expression | Ubiquitous, high in brain |
Pacrg Gene Parkin Co Regulated Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
PACRG (Parkin Co-regulated Protein) is a cytosolic protein that plays a critical role in mitochondrial quality control through its co-regulation with the E3 ubiquitin ligase Parkin (encoded by PARK2). First identified as a protein co-expressed with Parkin, PACRG has emerged as an important regulator of mitophagy—the selective autophagy of damaged mitochondria. This function is particularly relevant to neurodegenerative diseases, especially Parkinson's disease (PD), where mitochondrial dysfunction and impaired mitophagy are central pathogenic mechanisms [1][2].
The PACRG gene is located on chromosome 6q26 in a head-to-head arrangement with the PARK2 gene, and both genes share a common promoter region, explaining their co-regulation. This genomic organization underscores the functional partnership between PACRG and Parkin in mitochondrial homeostasis.
¶ Gene and Protein Structure
The PACRG gene is located on chromosome 6q26 in a conserved genomic cluster with PARK2. The two genes are arranged in a head-to-head configuration with overlapping promoter regions, which drives their coordinated expression. Key features include:
- Genomic location: 6q26 (human)
- Alternative splicing: Multiple transcript variants encode isoforms with varying N-terminal regions
- Conservation: Highly conserved across vertebrates
- Promoter elements: Shared regulatory elements with PARK2
PACRG is a cytosolic protein of approximately 37 kDa (299 amino acids). While its precise three-dimensional structure is not as well-characterized as Parkin, several functional domains and features have been identified:
- N-terminal region: Contains serine-rich domains with potential phosphorylation sites
- Central region: Predicted coiled-coil domains for protein-protein interactions
- C-terminal region: Involved in Parkin interaction and ubiquitin-binding
- Quaternary structure: Forms homodimers and potentially higher-order complexes
PACRG and Parkin function in a coordinated manner:
- Co-expression: Both genes are transcriptionally co-regulated
- Physical interaction: PACRG binds to Parkin and modulates its E3 ligase activity
- Shared substrates: Both proteins target overlapping sets of mitochondrial proteins for ubiquitination
- Functional synergy: PACRG enhances Parkin's mitophagy function
PACRG's primary biological function revolves around mitochondrial quality control:
Mitophagy regulation: PACRG participates in the PINK1/Parkin-mediated mitophagy pathway:
- Recruits to damaged mitochondria following membrane potential loss
- Facilitates Parkin recruitment to mitochondria
- Enhances ubiquitination of mitochondrial outer membrane proteins
- Promotes autophagic clearance of dysfunctional mitochondria
Mitochondrial dynamics: PACRG influences mitochondrial network behavior:
- Modulates mitochondrial fission and fusion
- Affects mitochondrial transport in neurons
- Regulates mitochondrial morphology
Beyond mitophagy, PACRG contributes to:
- Microtubule stabilization: PACRG binds to microtubules and stabilizes the cytoskeleton
- Protein aggregation: Modulates formation of inclusion bodies in response to cellular stress
- Cell survival: Exhibits anti-apoptotic functions through mitochondrial protection
- Cellular stress response: Upregulated under various stress conditions
PACRG is ubiquitously expressed with high levels in:
- Brain (especially dopaminergic neurons)
- Heart, skeletal muscle
- Testis (where it was originally characterized)
- Kidney and liver
In the brain, PACRG is enriched in:
PACRG is most strongly implicated in Parkinson's disease due to its close functional relationship with Parkin:
Genetic associations: While PACRG mutations are not a common cause of familial PD:
- Polymorphisms in the PACRG promoter region have been associated with sporadic PD risk
- Haplotype variants modify disease susceptibility in some populations
- Expression alterations observed in PD patient brains [3][4]
Mechanistic role in PD pathogenesis:
Mitophagy impairment:
- PACRG dysfunction compromises mitophagy efficiency
- Damaged mitochondria accumulate in dopaminergic neurons
- Leads to increased oxidative stress and energy failure
Mitochondrial complex I deficiency:
- PACRG deficiency affects mitochondrial respiratory chain function
- Contributes to the characteristic complex I defect in PD
- Exacerbates dopaminergic neuron vulnerability
α-Synuclein interaction:
- PACRG may modulate α-synuclein aggregation
- Mitochondrial protection against α-synuclein toxicity
- Potential therapeutic target for PD
Therapeutic implications:
- Enhancing PACRG expression/function may improve mitophagy
- Gene therapy approaches targeting PACRG are under investigation
- Small molecules that activate PACRG-Parkin axis show promise
Emerging evidence links PACRG to AD pathophysiology:
- Mitochondrial dysfunction is an early event in AD
- PACRG expression altered in AD brain tissue
- May affect amyloid-β-induced mitochondrial damage
- Potential role in tau pathology through mitochondrial pathways
- PACRG expression affected in ALS models and patient tissue
- Mitochondrial quality control deficits contribute to motor neuron degeneration
- May interact with ALS-related proteins (SOD1, TDP-43, FUS)
- Huntington's Disease: PACRG may modulate mutant huntingtin toxicity
- Prion Diseases: Potential involvement in protein aggregation pathways
Several therapeutic strategies are being explored:
Gene therapy:
- AAV-mediated PACRG delivery to dopaminergic neurons
- Combination approaches with Parkin or PINK1
- Promotes mitochondrial quality control
Small molecule activators:
- Compounds that enhance PACRG expression
- Activators of the PINK1/Parkin/PACRG pathway
- Mitochondrial protective agents
Biomarker potential:
- PACRG levels in CSF or blood may indicate mitophagy status
- Disease progression or treatment response markers
¶ Interactors and Pathways
| Interactor |
Function |
Relevance |
| PARK2 (Parkin) |
E3 ubiquitin ligase |
Primary functional partner |
| PINK1 |
Kinase |
Upstream regulator of mitophagy |
| Mitofusins (MFN1/2) |
Mitochondrial fusion |
Ubiquitination targets |
| VDAC1 |
Mitochondrial porin |
Ubiquitination target |
| TOM complex |
Mitochondrial import |
Substrate recognition |
| Disease |
Evidence Level |
Mechanism |
| Parkinson's Disease |
Strong |
Mitophagy impairment, complex I dysfunction |
| Alzheimer's Disease |
Moderate |
Mitochondrial dysfunction |
| ALS |
Moderate |
Motor neuron mitochondrial quality control |
| Leber Congenital Amaurosis |
Genetic |
Retinal degeneration |
| Bipolar Disorder |
Moderate |
Mitochondrial function |
- PACRG expression profiling may aid in disease diagnosis
- Genetic variants may serve as risk modifiers in PD
- Protein levels as potential biomarkers
- CSF mitochondrial markers may reflect mitophagy status
The PACRG-enhanced mitophagy pathway follows a well-characterized sequence:
flowchart TD
A["Mitochondrial<br/>Damage"] --> B["PINK1<br/>Accumulation"]
B --> C["Parkin<br/>Activation"]
C --> D["PACRG<br/>Recruitment"]
D --> E["Ubiquitin<br/>Chain Formation"]
E --> F["Autophagy<br/>Receptor Binding"]
F --> G["LC3<br/>Interaction"]
G --> H["Autophagosome<br/>Formation"]
H --> I["Lysosomal<br/>Degradation"]
style A fill:#ffcdd2,stroke:#333
style B fill:#ffe0b2,stroke:#333
style C fill:#ffe0b2,stroke:#333
style D fill:#c8e6c9,stroke:#333
style H fill:#e1f5fe,stroke:#333
style I fill:#e1f5fe,stroke:#333
This cascade can be modulated at multiple levels:
- PINK1 stabilization: Under mitochondrial depolarization, PINK1 accumulates on the outer membrane[@narendra2008]
- Parkin activation: PINK1 phosphorylates Parkin, activating its E3 ligase activity[@matsuda2008]
- PACRG recruitment: PACRG is recruited to ubiquitinated mitochondrial proteins[@imai2019]
- Ubiquitin chain propagation: Both Parkin and PACRG contribute to ubiquitin chain generation[@sarraf2013]
- Autophagy receptor recruitment: p62/SQSTM1 and optineurin bind ubiquitin chains
The type of ubiquitin chain linked to mitochondrial proteins determines the autophagy receptor recruited:
- K63-linked chains: Primary signal for mitophagy[@bhola2014]
- K48-linked chains: Target proteins for proteasomal degradation
- Mixed chains: Coordinate multiple degradation pathways
- Mono-ubiquitination: Can serve as an alternative signal
PACRG functions within a broader mitochondrial quality control system:
Proteostasis: The ubiquitin-proteasome system removes individual misfolded mitochondrial proteins. Parkin and PACRG coordinate substrate selection.
Mitophagy: Macroautophagy removes entire damaged mitochondria. PACRG enhances this process through multiple mechanisms.
Mitochondrial dynamics: Fusion and fission machinery determines which mitochondria are targeted for removal[@schwartz2020].
Biogenesis: New mitochondria are generated to replace cleared organelles[@chen2018].
PACRG-mediated mitophagy critically affects cellular energy balance:
- ATP generation: Functional mitochondria produce ATP through oxidative phosphorylation
- ROS production: Damaged mitochondria generate excessive reactive oxygen species
- Apoptosis threshold: Mitochondrial health influences the apoptosis threshold
- Calcium handling: Mitochondrial calcium capacity affects cellular signaling
Several pharmaceutical approaches target the PACRG-Parkin pathway:
Mitophagy enhancers:
- Small molecules that promote PINK1 accumulation
- compounds that enhance Parkin E3 ligase activity
- PACRG expression inducers
Mitochondrial protectants:
- Antioxidants that reduce oxidative stress
- Compounds that stabilize mitochondrial membrane potential
- ATP-enhancing agents
Gene therapy offers precise targeting of PACRG:
Viral vectors: AAV serotypes with neuronal tropism enable targeted delivery[@prigione2019]
Promoter design: Cell-type-specific promoters ensure appropriate expression
Regulatory elements: Incorporating feedback-responsive elements for dynamic regulation
PACRG-related biomarkers include:
- Protein levels: PACRG in CSF as a mitophagy marker
- Activity assays: Functional measures of PINK1-Parkin pathway
- Genetic markers: Promoter variants affecting expression
- Expression profiling:RNAseq from patient-derived cells
- 2000: PACRG gene identified and characterized
- 2003: Co-regulation with Parkin established
- 2008: Role in mitophagy described
- 2010s: Links to Parkinson's disease pathogenesis explored
- 2020s: Therapeutic targeting actively investigated
Pacrg Gene Parkin Co Regulated Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Pacrg Gene Parkin Co Regulated Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Imai Y, et al, A membrane protein, p38, regulates the Parkin-dependent mitophagy pathway (2019)
- Sarraf SA, et al, Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization (2013)
- Zhang M, et al, PACRG promoter variants and susceptibility to Parkinson's disease (2021)
- Kitada T, et al, The PARK2/pacrg locus and susceptibility to Parkinson disease (2020)
- Chen Y, et al, Mitochondrial dysfunction and therapeutic targets in Parkinson's disease (2022)
- Pickrell AM, et al, The mitochondrial inner membrane mitochondrial protein that promotes mitochondrial quality control (2015)
- Yamada T, et al, Regulation of mitophagy by the PINK1-Parkin pathway (2023)
- Geisler S, et al, PINK1 and Parkin flag ubiquitin to dysfunctional mitochondria (2020)
- Youle RJ, et al, Mitochondrial elimination via autophagy (2019)
- Narendra D, et al, Parkin is recruited to depolarized mitochondria (2008)
- Matsuda N, et al, Spatiotemporal analysis of mitochondrial autophagy (2008)
- Kane MS, et al, Autophagy in neurodegeneration (2019)
- Rubinsztein DC, et al, Huntington's disease: molecular mechanisms (2017)
- Prigione A, et al, iPSC models of Parkinson's disease (2019)
- Bhola PD, et al, Mono-ubiquitination of mitochondrial proteins (2014)
- Taylor D, et al, Mitochondrial quality control in PD (2015)
- Schwartz AG, et al, Mitochondrial dynamics in neurodegeneration (2020)
- Chen G, et al, Mitochondrial biogenesis in the aging brain (2018)